<DOC>
	<DOCNO>NCT01034306</DOCNO>
	<brief_summary>This trial test hypothesis administration CF101 , novel anti-inflammatory agent , patient rheumatoid arthritis high A3AR expression baseline relieve sign symptom disease .</brief_summary>
	<brief_title>Oral CF101 Tablets Treatment Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , parallel-group , placebo-controlled , study patient active RA high A3AR expression baseline randomize addition either CF101 1.0 mg placebo give orally q12h 12 week . Screening examination occur within 1 month prior dose . Washout disease-modifying antirheumatic drug ( DMARDs ) , include biological agent , occur prior dosing ; washout necessary , patient must re-qualify inclusion follow washout . Doses nonsteroidal anti-inflammatory drug ( NSAIDS ) corticosteroid must stable &gt; =1 month prior dose remain protocol participation . Disease activity assess use swollen tender joint count , physician patient global assessment ( visual analog scale , VAS ) , patient report pain ( VAS ) , Health Assessment Questionnaire ( HAQ ) Disability Index ( DI ) , Westergren erythrocyte sedimentation rate ( ESR , Screening , Weeks 0 and12 ) , C-reactive protein ( CRP ) level . Assessments take place Screening , Baseline ( Week 0 ) , Weeks 2 , 4 , 8 , 12 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Males female age 1875 year Meet criterion American College Rheumatology RA ( Arnett FC et al . Arthritis Rheum 1988 ; 31:315324 , Appendix 1 ) Not bed wheelchairbound Active RA , indicate presence ( ) &gt; =6 swollen joint ( 28 joint count ) ; AND ( b ) &gt; =6 tender joint ( 28 joint count ) ; AND either : ( c ) Westergren ESR &gt; =28 mm/hour ; OR ( ) CRP level upper limit normal central reference laboratory Elevated PBMC A3AR expression level , define &gt; = 1.5fold predetermine normal population standard , follow appropriate DMARD/biologic washout period ( see Exclusion Criteria ) within 2 week begin dose If take nonsteroidal antiinflammatory agent ( NSAID ) , dose stable least 1 month prior A3AR Qualification Visit , remain unchanged protocol participation If take oral corticosteroid , dose &lt; =10 mg/day prednisone equivalent , stable least 1 month prior A3AR Qualification Visit , remain unchanged protocol participation In Investigator 's opinion , ability understand nature study hazard participation , communicate satisfactorily Investigator participate , comply , requirement entire protocol Negative screening serum pregnancy test female patient childbearing potential Females childbearing potential must utilize , throughout course trial , 2 method contraception deem adequate Investigator ( example , oral contraceptive pill plus barrier method ) All aspect protocol explain write informed consent obtain Receipt follow least 1 month washout period prior A3AR Qualification Visit : methotrexate , sulfasalazine , oral injectable gold , azathioprine , minocycline , penicillamine , anakinra Receipt etanercept least 6 week washout period prior A3AR Qualification Visit Receipt chloroquine , hydroxychloroquine , cyclosporine , infliximab , golimumab adalimumab least 2 month washout period prior A3AR Qualification Visit Receipt leflunomide least 2 month washout period prior A3AR Qualification Visit , unless patient undergone cholestyramine washout least 1 month prior test Receipt cyclophosphamide least 6 month period prior A3AR Qualification Visit Receipt rituximab previous time Previous failure respond methotrexate antirheumatic biological agent Participation previous trial CF101 trial Use oral corticosteroid &gt; 10 mg prednisone , equivalent , per day Change NSAID dose level 1 month prior A3AR Qualification Visit Change oral corticosteroid dose level 1 month prior A3AR Qualification Visit Receipt parenteral intraarticular corticosteroid 1 month prior A3AR Qualification Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>